Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

• Status: Terminated
• Trial end date: 2021-06-16
• Target enrollment: 0
• Participant gender: Male

Summary

Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus docetaxel who have an identified related female donor (mother sister, daughter, second degree relative such as granddaughter or niece) will undergo bone marrow transplantation followed by post-transplant Cytoxan (PT/Cy) and testosterone.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Treatments: Cyclophosphamide; Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Performance status ≤1

• Age ≥18 years and ≤ 75 years old

• Histologically-confirmed adenocarcinoma of the prostate

• Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist) with documented castrate level of serum testosterone (<50 ng/dl)

• Metastatic disease radiographically documented by CT or bone scan

• Patient must be HLA typed at high resolution using DNA based typing at the following loci: HLA-A, -B, -C, and DRB1

• Patient must have available one or more potential first (biologic mother, sister, half-sister, or daughter) or second-degree related female donor. Mothers and daughters have a 100% chance of being haploidentical matches, sisters a 75% chance of being matched or haploidentical, and second degree relatives have a 50% chance of being haploidentical matches. The donor and recipient must be HLA identical for at least one antigen at HLA-A, -B, -C and HLA-DRB1.

• Screening PSA must be ≥ 1.0 ng/mL.

• Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509).

• Prior docetaxel (≤ 6 cycles) as first line therapy

• Cardiac ejection fraction at rest must be ≥ 40%

• Acceptable liver function: Bilirubin < 2.5 mg/dL (unless due to Gilbert's disease, AST (SGOT) and ALT (SGPT) < 5 times upper limit of normal.

• Acceptable renal function: Serum creatinine within normal range.

• Pulmonary function: DLCO (corrected for hemoglobin), FEV1 and FVC >50% predicted.

• At least 4 wks since prior radiation or surgery with full recovery (no persistent toxicity ≥ Grade 1)

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Prior treatment with Sipuleucel-T, radium-223, strontium-89, or samarium-153

• Prior chemotherapy (docetaxel, cabazitaxel) for castrate resistant prostate cancer

• Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study

• Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C.

• Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.